IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immunome Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 11, 2026
$16.77+0.30 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.90B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-3228.8%
Net margin
-3060.0%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -23.2% | – | – | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -624.2% | -52.1% | |
| Return on assets | – | -71.9% | -46.0% | |
| Current ratio | – | 14.12 | 14.69 | |
| Interest coverage | – | -583.9× | – | |
| Capex to revenue | – | – | 139.5% | |
| Diluted shares | – | 3M | 87M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Immunome generated $356.20M from operations and spent $18.02M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$356.20M
Used
$18.02M
Capital expenditure$18.02M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3060.0%
×Asset turnover0.02×
×Equity multiplier1.13×
=Return on equity, FY2025-52.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -3060.0% | 0.02× | 1.13× | -52.1% |
| FY2024 | -3240.4% | 0.05× | 1.29× | -194.6% |
| FY2023 | -761.9% | 0.16× | 1.26× | -156.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$212.39M
- Cash generatingOperating cash flow above zero-$190.92M
- Return on assets improvedROA up on the prior year-197.2% → -88.4%
- Earnings backed by cashOperating cash flow above net income-$190.92M vs -$212.39M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.08 → 14.69
- No dilutionShare count did not rise59M → 87M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.06 → 0.03